Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

Date publication

août 2012

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel , Dr KAMINSKY Marie-Christine , Dr ZANETTA Sylvie

Tous les auteurs :
Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22234739

Résumé

Preclinical studies suggest that insulin-like growth factor-1 receptor (IGF-1R) blockage could be a promising therapeutic target in squamous cell carcinoma of the head and neck (SCCHN). Therefore, we investigated the efficacy and toxicity of figitumumab, an anti-IGF-1R monoclonal antibody, in palliative SCCHN.

Mots clés

Antibodies, Monoclonal, Biopsy, Carcinoma, Squamous Cell, blood, Gene Expression Profiling, Head and Neck Neoplasms, blood, Humans, Immunoglobulins, Intravenous, adverse effects, Receptor, IGF Type 1, antagonists & inhibitors, Reverse Transcriptase Polymerase Chain Reaction

Référence

Ann. Oncol.. 2012 Aug;23(8):2153-61